A novel parC mutation potentiating fluoroquinolone resistance in Klebsiella pneumoniae and Escherichia coli clinical isolates

Introduction: Resistance to fluoroquinolones is mainly due to point mutations that gave rise to amino acid substitutions in the quinolone resistance-determining regions of either gyrA or parC genes, which may be augmented by plasmid mediated resistance. Accordingly, the main aim of the study was to...

Full description

Saved in:
Bibliographic Details
Main Authors: Marwa Atef Yakout, Ghada Hani Ali
Format: Article
Language:English
Published: The Journal of Infection in Developing Countries 2022-02-01
Series:Journal of Infection in Developing Countries
Subjects:
Online Access:https://jidc.org/index.php/journal/article/view/15142
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849313669715853312
author Marwa Atef Yakout
Ghada Hani Ali
author_facet Marwa Atef Yakout
Ghada Hani Ali
author_sort Marwa Atef Yakout
collection DOAJ
description Introduction: Resistance to fluoroquinolones is mainly due to point mutations that gave rise to amino acid substitutions in the quinolone resistance-determining regions of either gyrA or parC genes, which may be augmented by plasmid mediated resistance. Accordingly, the main aim of the study was to investigate the mutations in gyrA and parC genes as well as the qnrA and qnrB genes acquisition. Methodology: 193 Klebsiella pneumoniae and Escherichia coli isolates were collected, identified and MICs for ciprofloxacin, levofloxacin and moxifloxacin were determined. Polymerase Chain Reaction to investigate qnrA, qnrB, gyrA and parC genes followed by DNA sequencing analysis to identify mutations in gyrA and parC genes. Results: The most prominent mutation in gyrA gene was ser83leu, followed by asp87asn, and lys154arg. Regarding parC mutations, ser80ile was the most detected. Other mutations val141ala and glu84ala were also noted. In addition to a substitution mutation at codon 157 of leucine to tyrosin. To the best of our knowledge this mutation was not previously reported. qnrB was the most detected gene, as 64.7% Klebsiella pneumoniae and 57.1% Escherichia coli were positive. qnrA gene was detected in 11% Klebsiella pneumoniae and 4% of Escherichia coli isolates tested. Conclusions: This study suggests that the indiscriminate use of fluoroquinolones resulted in the increase of development of resistance either through mutations in the quinolone resistance-determining regions of either gyrA or parC genes augmented by plasmid mediated resistance. The irrational use of new fluoroquinolones such as moxifloxacin has created selective pressure for the appearance of new mutation.
format Article
id doaj-art-8b16d1cb84784af28362a7b9f74ed71a
institution Kabale University
issn 1972-2680
language English
publishDate 2022-02-01
publisher The Journal of Infection in Developing Countries
record_format Article
series Journal of Infection in Developing Countries
spelling doaj-art-8b16d1cb84784af28362a7b9f74ed71a2025-08-20T03:52:42ZengThe Journal of Infection in Developing CountriesJournal of Infection in Developing Countries1972-26802022-02-01160210.3855/jidc.15142A novel parC mutation potentiating fluoroquinolone resistance in Klebsiella pneumoniae and Escherichia coli clinical isolatesMarwa Atef Yakout0Ghada Hani Ali1Department of Microbiology and immunology, Faculty of pharmacy, Pharos University in Alexandria, Alexandria, EgyptDepartment of Microbiology and immunology, Faculty of pharmacy, Pharos University in Alexandria, Alexandria, Egypt Introduction: Resistance to fluoroquinolones is mainly due to point mutations that gave rise to amino acid substitutions in the quinolone resistance-determining regions of either gyrA or parC genes, which may be augmented by plasmid mediated resistance. Accordingly, the main aim of the study was to investigate the mutations in gyrA and parC genes as well as the qnrA and qnrB genes acquisition. Methodology: 193 Klebsiella pneumoniae and Escherichia coli isolates were collected, identified and MICs for ciprofloxacin, levofloxacin and moxifloxacin were determined. Polymerase Chain Reaction to investigate qnrA, qnrB, gyrA and parC genes followed by DNA sequencing analysis to identify mutations in gyrA and parC genes. Results: The most prominent mutation in gyrA gene was ser83leu, followed by asp87asn, and lys154arg. Regarding parC mutations, ser80ile was the most detected. Other mutations val141ala and glu84ala were also noted. In addition to a substitution mutation at codon 157 of leucine to tyrosin. To the best of our knowledge this mutation was not previously reported. qnrB was the most detected gene, as 64.7% Klebsiella pneumoniae and 57.1% Escherichia coli were positive. qnrA gene was detected in 11% Klebsiella pneumoniae and 4% of Escherichia coli isolates tested. Conclusions: This study suggests that the indiscriminate use of fluoroquinolones resulted in the increase of development of resistance either through mutations in the quinolone resistance-determining regions of either gyrA or parC genes augmented by plasmid mediated resistance. The irrational use of new fluoroquinolones such as moxifloxacin has created selective pressure for the appearance of new mutation. https://jidc.org/index.php/journal/article/view/15142Klebsiella pneumoniaEscherichia coligyrAparCFluoroquinolonesMutations
spellingShingle Marwa Atef Yakout
Ghada Hani Ali
A novel parC mutation potentiating fluoroquinolone resistance in Klebsiella pneumoniae and Escherichia coli clinical isolates
Journal of Infection in Developing Countries
Klebsiella pneumonia
Escherichia coli
gyrA
parC
Fluoroquinolones
Mutations
title A novel parC mutation potentiating fluoroquinolone resistance in Klebsiella pneumoniae and Escherichia coli clinical isolates
title_full A novel parC mutation potentiating fluoroquinolone resistance in Klebsiella pneumoniae and Escherichia coli clinical isolates
title_fullStr A novel parC mutation potentiating fluoroquinolone resistance in Klebsiella pneumoniae and Escherichia coli clinical isolates
title_full_unstemmed A novel parC mutation potentiating fluoroquinolone resistance in Klebsiella pneumoniae and Escherichia coli clinical isolates
title_short A novel parC mutation potentiating fluoroquinolone resistance in Klebsiella pneumoniae and Escherichia coli clinical isolates
title_sort novel parc mutation potentiating fluoroquinolone resistance in klebsiella pneumoniae and escherichia coli clinical isolates
topic Klebsiella pneumonia
Escherichia coli
gyrA
parC
Fluoroquinolones
Mutations
url https://jidc.org/index.php/journal/article/view/15142
work_keys_str_mv AT marwaatefyakout anovelparcmutationpotentiatingfluoroquinoloneresistanceinklebsiellapneumoniaeandescherichiacoliclinicalisolates
AT ghadahaniali anovelparcmutationpotentiatingfluoroquinoloneresistanceinklebsiellapneumoniaeandescherichiacoliclinicalisolates
AT marwaatefyakout novelparcmutationpotentiatingfluoroquinoloneresistanceinklebsiellapneumoniaeandescherichiacoliclinicalisolates
AT ghadahaniali novelparcmutationpotentiatingfluoroquinoloneresistanceinklebsiellapneumoniaeandescherichiacoliclinicalisolates